Agenus

Deal terminate tear up end deal scrap
Biotech

BMS ditches TIGIT, ending $200M bet on Agenus bispecific

BMS is axing another big bet from the Caforio era, terminating a deal for Agenus' TIGIT bispecific after paying $200 million to buy into the program.
Nick Paul Taylor Aug 5, 2024 9:17am
Image of a neon sign with the word no lit up next to an unlit yes

FDA wrecks Agenus’ accelerated approval plan

Jul 18, 2024 8:01am
BMS

BMS trims anti-TIGIT and a handful of other meds

Sep 14, 2023 1:57pm
graphic image of stick figures being pushed out of a line indicating theyre being removed or fired

Agenus lays off 25%, sidelines programs to focus on cancer combo

Aug 23, 2023 11:04am
ovarian cancer cancer awareness

Agenus gets boost for combo drug, this time in ovarian cancer

Mar 27, 2023 9:45am
On target clinical trial success bullseye score

Combo may offer route back for Agenus' cervical cancer drug

Jan 23, 2023 10:47am